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SUMMARY
Purinergic receptors and nucleotide-binding domain
leucine-rich repeat containing (NLR) proteins have
been shown to control viral infection. Here, we
show that the NLR family member NLRP3 and the
purinergic receptor P2Y2 constitutively interact and
regulate susceptibility to HIV-1 infection. We found
that NLRP3 acts as an inhibitory factor of viral entry
that represses F-actin remodeling. The binding of
the HIV-1 envelope to its host cell receptors (CD4,
CXCR4, and/or CCR5) overcomes this restriction by
stimulating P2Y2. Once activated, P2Y2 enhances
its interaction with NLRP3 and stimulates the recruit-
ment of the E3 ubiquitin ligase CBL to NLRP3,
ultimately leading to NLRP3 degradation. NLRP3
degradation is permissive for PYK2 phosphorylation
(PYK2Y402*) and subsequent F-actin polymeriza-
tion, which is required for the entry of HIV-1 into
host cells. Taken together, our results uncover a
mechanism by which HIV-1 overcomes NLRP3 re-
striction that appears essential for the accomplish-
ment of the early steps of HIV-1 entry.
INTRODUCTION
Although the stimulation of innate immunity with vaccine adju-
vants has been extensively and efficiently harnessed for the con-
trol of major infectious diseases (such as diphtheria, tetanus, and
poliomyelitis), the cellular and molecular mechanisms that
orchestrate immune responses against pathogens remain
largely elusive, especially with respect to the early steps of infec-
tion. Immune sensing of HIV-1 by pathogen recognition recep-
tors (PPRs) and cytoplasmic DNA sensors may partially hinder
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Figure 1. NLRP3 and P2Y2 Interaction Is Enhanced during HIV-1 and SIV Infections
(A) Immunoprecipitations were performed in THP1 cells after 3 h of X4-tropic HIV-1NL4-3 infection and analyzed by western blot. The asterisk indicates an un-
specific band. Representative western blots of three independent experiments are shown. See also Figure S1A.
(B–D) Confocal microscopy images of NLRP3 (B and C), gp120 (B), and P2Y2 (C) polarizations during HIV-1-infected and uninfected lymphocyte interactions.
Images are representative of three different donors. The frequency of NLRP3 polarization (D) is shown. Data are presented as means ± SEM, and significance is
****p% 0.0001 (n = 366 virological synapses from 3 independent experiments), unpaired Mann-Whitney test.
(legend continued on next page)
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HIV-1 replication through the production of type-1 interferon
(IFN) and the expression of restriction factors such as APOBEC3
cytidine desaminases, tetherin, and SAM domain and HD
domain-containing protein 1 (SAMHD1) (Towers and Noursade-
ghi, 2014). Despite the beneficial impact of the cell-autonomous
innate immune system on HIV-1 replication, innate signals,
converging on the DNA sensing interferon gamma inducible 16
protein (IFI16) inflammasome, can contribute to chronic immune
activation and eventually to pyroptosis of uninfected CD4+
T cells, thereby enhancing disease progression (Doitsh et al.,
2010, 2014; Monroe et al., 2014). Given the ambiguous effects
of innate immune signals on HIV-1 replication and disease pro-
gression, further exploration of the innate signaling molecular
pathways that govern HIV-1 infection is needed.
Most studies on HIV-1 infection have explored innate mecha-
nisms acting before or after viral entry. Little is known about
innate signaling pathways elicited during viral entry. We previ-
ously reported that purinergic receptors, which are membrane-
anchored PPRs, promote the entry of HIV-1 into immune cells
(Se´ror et al., 2011). The binding of HIV-1 envelope (Env) to its
cellular receptors (CD4, CXCR4, and/or CCR5) causes the
release of adenosine triphosphate (ATP) from host cells through
the opening of pannexin-1 hemichannels (PNX1). Once released,
extracellular ATP stimulates purinergic receptors (including the
purinergic receptor P2Y2) and facilitates the membrane fusion
process through the activation of the proline-rich tyrosine kinase
2 (PYK2) that is required for viral entry (Se´ror et al., 2011). The
activation of the purinergic signaling pathway is indispensable
for cell-free HIV-1 infection (Hazleton et al., 2012; Se´ror et al.,
2011; Swartz et al., 2014), as well as for cell-to-cell transmission
of the virus between infected lymphocytes and target cells,
which is the most efficient route of HIV-1 spreading (Se´ror
et al., 2011; Swartz et al., 2014). In this context, antagonists of
purinergic receptors or pannexin-1 have emerged as a new class
of HIV-1 microbicides (Se´ror et al., 2011).
Other PPRs, the NOD-like receptors (NLRs), have also been
involved in the establishment of viral infection. Initially described
as crucial for sensing and initiating host defense in viral infection
through the formation of inflammasome (Chen and Ichinohe,
2015), NLRs (such as NLRX1) have recently been shown to be
involved in the early innate response to simian immunodefi-
ciency virus (SIV) infection and to contribute to viral replication
by repressing the transcription of restriction factors (such as
the interferon stimulated gene [ISG] 5, the myxovirus resistance
2 protein [MX2], and the tripartite motif-containing protein [TRIM]
5; Barouch et al., 2016). These results highlight the counterintu-
itive role of the inflammasome signaling, which indeed may
facilitate (rather than repress) the early steps of HIV and SIV
infections.
In this context and to further characterize cellular factors that
may modulate P2Y2-dependent signaling during the early steps
of HIV-1 infection, we studied the role of NLRs during viral
infection. We identified the NACHT, LRR and PYD domains-con-
taining protein 3 (NLRP3) as a P2Y2-interacting protein. Consid-
ering that NLRP3 and P2Y2 are endogenously expressed in
CD4+ T cells and cells from mononuclear phagocyte lineage
(including monocytes and macrophages), we first studied the
interaction between NLRP3 and P2Y2 during the cellular infec-
tion by HIV-1 and SIV. Then we characterized the biological
consequences of the modulation of this interaction during the
early steps of infection of macrophages, which are, together
with T lymphocytes, the major target cells of HIV-1.
RESULTS
Enhancement of the Interaction between NLRP3 and
P2Y2 during SIV and HIV Infection
Based on our previous work showing that the purinergic recep-
tor P2Y2 contributes to the early steps of HIV-1 infection (Se´ror
et al., 2011), we searched for potential P2Y2-interacting NLR
proteins, identifying NLRP3 as an interactor of P2Y2 (Figure 1A).
The endogenous NLRP3 and P2Y2 proteins co-immunoprecip-
itated in human THP1 monocytes (Figure 1A), indicating that
both proteins constitutively interact. Of note, this interaction
increased after 3 h of infection of human THP1 monocytes
with CXCR4-tropic (X4-tropic) HIV-1NL4-3 (Figures 1A and
S1A). We then studied the subcellular localization of NLRP3
during the early steps of HIV-1 infection obtained by co-
culturing of uninfected peripheral blood lymphocytes (PBLs)
with X4-tropic HIV-1NDK-infected PBLs. NLRP3 polarized to-
ward the contact sites formed between HIV-1NDK-infected
and uninfected host cells (Figures 1B and 1C). At these contact
sites, NLRP3 colocalized with the glycoprotein gp120 (Fig-
ure 1B) and the purinergic receptor P2Y2 (Figure 1C). Thus,
NLRP3 accumulated at the virological synapse that is formed
between HIV-1NDK -infected and uninfected PBLs (Figure 1D).
(E and F) PLA between P2Y2 andNLRP3 (E) and frequencies of positive signals (F) detected on interacting HIV-1-infected and uninfected lymphocytes are shown.
The image is representative of three different donors. Data are presented as means ± SEM, and significance is *p% 0.05 (n = 29 virological synapses from three
independent experiments), unpaired Mann-Whitney test.
(G) Fluorescence intensities of NLRP3 in HIV-1-infected and uninfected lymphocytes obtained from confocal microscopy are shown a three-dimensional (3D)
Z-projection. Representative experiment of three different donors is shown.
(H and I) PLA between P2Y2 and NLRP3 (H) and frequencies of positive signals detected on ileum sections (I) obtained from SIVmac251-infected and uninfected
Macaca fascicularis are shown. Images are representative of four SIVmac251-infected and three uninfected Macaca fascicularis. Data are presented as means ±
SEM, and significance is ****p% 0.0001 (n = 3 uninfected, n = 4 uninfected), unpaired Mann-Whitney test.
(J and K) PLA between P2Y2 andNLRP3 (J) and frequencies of positive signals detected on brain autopsies (K) fromHIV-1-infected and uninfected individuals are
shown. Images are representative of nine HIV-1-infected and two uninfected donors. Data are presented as means ± SEM, and significance is **p% 0.01 (n = 2
uninfected, n = 9 infected), unpaired Mann-Whitney test.
(L and M) PLA between P2Y2 and NLRP3 (L) and frequencies of positive signals (M) detected during MDMs infection are shown. The image is representative of
three different donors. Data are presented as means ± SEM, and significance is ****p% 0.0001 (n = 1,075 and 1,133 for uninfected and HIV-1BaL infected MDMs,
respectively), unpaired Mann-Whitney test.
See also Figure S1.
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We determined the ability of NLRP3 to directly interact with
P2Y2 by means of a proximity ligation assay (PLA). During the
early steps of HIV-1 infection, the interaction between NLRP3
and P2Y2 mostly occurred at the contact sites between
HIV-1NDK-infected and uninfected T lymphocytes (Figures 1E
and 1F). These results suggest that the interaction between
NLRP3 and P2Y2 may regulate the viral entry into target cells.
We also studied the subcellular localization of NLRP3 after
chronic infection of PBLs with X4-tropic HIV-1NDK for 72 h
(Figures 1G and S1B–S1D) or that of monocyte-derived
macrophages (MDMs) with R5-tropic HIV-1AD8 for 6 days
(Figures S1E and S1F). While NLRP3 presented a diffuse
cytosolic expression pattern in uninfected target cells, it
aggregated in the cytoplasm and at the membrane of infected
PBLs (Figures 1G and S1B–S1D) or MDMs (Figures S1E and
S1F). Using PLA, we also evaluated the ability of NLRP3 to
interact with P2Y2 during chronic infection and revealed that
the interaction between NLRP3 and P2Y2 increased in
Figure 2. NLRP3 Inflammasome Activation
Impairs HIV-1 Entry
(A and B) HIV-1 CAp24 content in cell supernatant
analyzed by ELISA at 3 and 6 days (A) and intra-
cellular CAp24 analyzed by flow cytometry at
6 days (B) after R5-tropic HIV-1BaL infection of
LPS- or MSU-treated MDMs. Data obtained from
n = 3 independent experiments are presented in (A)
as means ± SEM. Significance levels are **p
% 0.01, ***p % 0.001, and ****p % 0.0001, un-
paired Mann-Whitney test. Representative flow
cytometry analyses of three independent experi-
ments are shown in (B).
(C and D) Intracellular CAp24 analyzed by western
blot and the corresponding quantifications of
control or MSU-treated MDMs that were infected
for 6 h with R5-tropic HIV-1AD8 (C) or HIV-1VSV-G
(D). Representative western blots from three in-
dependent donors are shown. Data are obtained
from three independent experiments presented as
means ± SEM. Significance levels are **p % 0.01
(n = 3 donors), unpaired t test.
(E) The number of copies of early reverse tran-
scripts of HIV-1 (HIV-1 ERT) analyzed by qPCR in
MDMs pretreated with 100 mM MSU for 18 h and
infected for 6 h with HIV-1AD8 in the presence of
MSU. ERT data were determined for three donors
at 24 h after infection. Significance is *p % 0.05
(n = 3 donors), Wilcoxon signed rank test.
See also Figures S2A, S2B, and S2C.
chronically infected tissues (e.g., ileum
[Figures 1H and 1I] and colon [Figures
S1G and S1H] from SIV-1mac251-infected
non-human primateMacaca fascicularis,
the frontal cortex from untreated HIV-1
carriers [as compared with uninfected
controls; Figures 1J and 1K]), as well
as in chronically infected PBLs (Figures
S1I and S1J) or MDMs (Figures 1L and
1M). Altogether, these findings indicate
that the interaction between NLRP3
and P2Y2 increased during acute and chronic steps of viral
infection.
NLRP3 Inflammasome Activation Impairs HIV-1 Entry
into Host Cells
To characterize the role of NLRP3-P2Y2 interaction and related
signaling pathways during the early steps of HIV-1 infection,
we first evaluated the possibility that the NLRP3 might affect
viral replication through the formation of the inflammasome.
Considering that sterile particulates such as monosodium
urate (MSU) crystals are capable of activating the NLRP3
inflammasome (Shi et al., 2010), we incubated MDMs with
100 mM MSU before infection with R5-tropic HIV-1BaL and
then analyzed their viral permissiveness. The activation of
the NLRP3 inflammasome by MSU reduced the release of
CAp24 capsid from human MDMs (Figure 2A) and its intracel-
lular detection (Figure 2B) after 3 days (Figure 2A) and 6 days
(Figures 2A and 2B) of infection with R5-tropic HIV-1BaL. This
3384 Cell Reports 28, 3381–3394, September 24, 2019
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MSU-mediated inhibition of HIV-1 was more efficient than the
one detected with lipopolysaccharide (LPS) (Figures 2A and
2B). To further characterize the impact of NLRP3 inflamma-
some activation on the early steps of HIV-1 infection, we
monitored the effects of MSU treatment on intracellular HIV-1
CAp24 capsid levels (after removal of membrane bound non-
internalized virus with trypsin treatment) and on the early
reverse transcripts that are detected after 6 and 24 h, respec-
tively, of infection of human MDMs with R5-tropic HIV-1AD8.
These data revealed that NLRP3 inflammasome activation
impaired the accumulation of intracellular HIV-1 CAp24 capsid
(Figure 2C) and subsequently reduced the early reverse
transcripts (Figure 2E) without affecting cell viability
(Figure S2A) nor the membrane expression of the viral recep-
tors CD4 (Figure S2B) and CXCR5 (Figure S2C). Accordingly,
MSU did not impair the accumulation of intracellular HIV-1
CAp24 capsid in human MDMs that were infected by the
HIV-1NL4-3DENV variant (defective in viral envelope) pseudo-
typed with the vesicular stomatitis virus G protein (VSV-G) en-
velope, HIV-1VSV-G (Figure 2D). Altogether, these results
demonstrate that NLRP3 inflammasome activation inhibits
HIV-1 entry into host cells.
NLRP3 Protein Inhibits HIV-1 Infection by Repressing
the Cytoskeletal Remodeling Required for HIV-1 Entry
We determined the role of NLRP3 inflammasome protein during
the early steps of HIV-1 infection through the knockdown of
NLRP3 using specific short hairpin RNA (shRNA). We observed
that the depletion of NLRP3 increased the release of CAp24
capsid from human MDMs (Figure 3A and S3A), THP1 mono-
cytes (Figures 3B, 3C, and S3B), and CEM-SS T cells (Figures
3D, 3E, and S3C) after 6, 11, or 12 days of infection with
R5-tropic HIV-1AD8 (Figures 3A, 3C, and 3E) or X4-tropic
HIV-1NL4-3 (Figures 3B and 3D). After removing membrane-
bound non-internalized HIV-1 particles by trypsinizing the
cells, western blot detection of intracellular CAp24 capsid
corroborated that the depletion of NLRP3 in MDMs increased
cellular susceptibility to HIV-1 infection after 6 h of infection
(Figure 3F). These data were confirmed by the depletion of
NLRP3 in THP1 monocytes that were then infected with
X4-tropic HIV-1NL4-3 for 6 h (Figures 3G and S3D). To rule out
the possibility that NLRP3 protein may also act at post-entry
levels, we evaluated the effects of NLRP3 overexpression on
viral yields after transfection of X4-tropic HIV-1NL4-3 (Figure S3E)
or R5-tropic HIV-1AD8 (Figure S3F) DNA constructs that
subsequently produce infectious virions. NLRP3 overexpression
(Figures S3E and S3F) did not impact the amount and infectivity
of X4-tropic HIV-1NL4-3 (Figures S3G and S3I) and R5-tropic HIV-
1AD8 (Figures S3H and S3J) produced 48 h post transfection.
Consistently, the depletion of NLRP3 failed to increase infection
of target cells by HIV-1VSV-G (Figures 3H and S3K). These results
imply that NLRP3 protein selectively inhibits receptor-mediated
entry of HIV-1.
Emerging evidence has revealed important inflammasome-in-
dependent roles for ASC and CASP1 in controlling immune re-
sponses through the modulation of F-actin polymerization
(Caution et al., 2015; Ippagunta et al., 2011). In our previous
report (Se´ror et al., 2011), we demonstrated that following
HIV-1 infection, P2Y2 enhances plasma membrane depolariza-
tion through the activating autophosphorylation of the proline-
tyrosine kinase 2 (PYK2) on tyrosine residue 402 (PYK2Y402*)
to favor the early fusion of the HIV-1 membrane and the target
cell. Importantly, activated PYK2 is known to broadly modulate
the F-actin rearrangement and polymerization to regulate
immune cells migration, morphology or growth (Collins et al.,
2010; Du et al., 2001; Okigaki et al., 2003; Ren et al., 2001;
Wang et al., 2003). F-actin remodeling is also required for
HIV-1membrane fusionwith target cells and entry (Jime´nez-Bar-
anda et al., 2007; Stolp and Fackler, 2011). Considering
that F-actin cytoskeletal remodeling and the associated PYK2
activation both contribute to HIV-1 early viral entry (Jime´nez-Bar-
anda et al., 2007; Se´ror et al., 2011; Stolp and Fackler, 2011),
Figure 3. NLRP3 Inhibits HIV-1 Entry by Repressing F-Actin Polymerization
(A) HIV-1 CAp24 in cell supernatant analyzed by ELISA of control and NLRP3-depleted MDMs infected with HIV-1AD8 after 6 and 11 days of infection. Data are
presented as means ± SEM, and significance levels are *p % 0.05 and ****p % 0.0001 (n = 3 independent donors), unpaired Mann-Whitney test. See also
Figure S3A.
(B and C) HIV-1 CAp24 in cell supernatant analyzed by ELISA of control and NLRP3-depleted THP1 monocytes infected with X4-tropic HIV-1NL4-3 (B) and
R5-tropic HIV-1AD8 (C) after 6 and 12 days of infection. Data are presented as means ± SEM, and significance is ****p% 0.0001 (n = 3 independent experiments),
unpaired t test. See also Figure S3B.
(D and E) HIV-1 CAp24 in cell supernatant analyzed by ELISA of control and NLRP3-depleted CEM-SS T cells infected with X4-tropic HIV-1NL4-3 (D) and R5-tropic
HIV-1AD8 (E) after 6 and 12 days of infection. Data are presented as means ± SEM, and significance is ****p% 0.0001 (n = 3 independent experiments), ANOVA
test. See also Figure S3C.
(F) Intracellular CAp24 analyzed by western blot in control and NLRP3-depleted MDMs, which were infected for 6 h with R5-tropic HIV-1AD8. Representative
western blots of three independent donors are shown. See also Figures S3D and S3K.
(G and H) Intracellular HIV-1 CAp24 analyzed by western blot in control and NLRP3-depleted THP1 cells infected for 6 h with X4-tropic HIV-1NL4-3 (G) or
HIV-1NL4-3DEnv pseudotyped with VSV-G envelope (H). Representative western blots of three independent experiments are shown.
(I) Confocal microscopy images of HIV-1 entry (detected with CAp24 and Vpr-GFP signals) in THP1 macrophages control and depleted for P2Y2 (shP2Y2) or for
NLRP3 (shNLRP3-1 and 2) and infected for 6 h with R5-tropic HIV-1AD8-Vpr-GFP in the presence or absence of latrunculin B (10 mM). Dashed lines indicate the
cellular perimeters. The corresponding F-actin polymerization staining (with phalloidin) is shown in Figure S3L. Images are representative of three independent
experiments.
(J) Cell percentage of HIV-1AD8-Vpr-GFP and F-actin polymerization positive cells determined by confocal microscopy as shown in (I) and in Figure S3L. Data
obtained from three independent experiments are presented as means ± SEM (n = 300 cells). Significance levels are *p% 0.05 and ****p% 0.0001, ANOVA test.
(K) NLRP3, PYK2Y402*, PYK2, and intracellular CAp24 analyzed by western blot of control and NLRP3-depleted THP1 macrophages pretreated 18 h with
AR-C118925XX (100 mM) and infected with R5-tropic HIV-1AD8 for 6 h treated in the presence of the drug. Western blots are representative of three independent
experiments.
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we hypothesized that NLRP3 may antagonize the effects of acti-
vated P2Y2 and PYK2 on F-actin remodeling upon HIV-1 infec-
tion, thereby inhibiting HIV-1 entry. Confocal microscopy anal-
ysis revealed that NLRP3 depletion increased the entry of
GFP-fused viral protein (Vpr) containing viral particles (HIV-
1AD8-Vpr-GFP) (McDonald et al., 2002) into PMA-THP1 macro-
phages, as revealed by the intracellular detection of HIV-1AD8-
Vpr-GFP and CAp24 (Figures 3I and 3J). The enhanced viral entry
into NLRP3-depleted cells was associated with an increase of
F-actin cytoskeletal polymerization (Figures 3J and S3L). More-
over, inhibition of F-actin polymerization by latrunculin B abro-
gated the stimulation of HIV-1 infection by NLRP3 depletion
(Figures 3I, 3J, and S3L). Consistently, the selective P2Y2 antag-
onist AR-C118925XX abrogated the NLRP3 depletion-driven
signaling pathway (as revealed by the decreased of PYK2402*
and intracellular CAp24 level [Figure 3K]) in NLRP3-depleted
THP1 macrophages that were infected with R5-tropic HIV-1AD8
for 6 h. Altogether, these results demonstrate that, indepen-
dently from its contribution to the inflammasome, NLRP3 protein
acts as an endogenous repressor of F-actin cytoskeletal poly-
merization that facilitates the P2Y2-dependent entry of HIV-1
into target cells.
NLRP3 Is Degraded during the Early Steps of HIV-1
Infection
To determine how HIV-1 may overcome the NLRP3-mediated
inhibition of its entry into host cells, we simultaneously
measured NLRP3 and P2Y2 expressions during infection.
Figure 4. NLRP3 Expression Is Decreased during the Early Steps of HIV-1 Infection
(A–C) NLRP3 and P2Y2 expressions in MDMs (A), THP1 cells (B), and PHA/IL-2-stimulated human lymphocytes (C) that were infected, respectively, during
indicated times (A), 6 h (B), or 3 h (C) with indicated viruses. Intracellular CAp24 level is also shown in (A). Representative western blots of three independent
experiments are shown. The relative NLRP3 expression data from n = 3 independent experiments are presented as means ± SEM. Significance levels are **p%
0.01, ***p% 0.001, and ****p% 0.0001, unpaired t test.
(D) THP1 cells were infected for 6 h with X4-tropic HIV-1NL4-3 in the presence of 1 mM G5 and analyzed by western blot for NLRP3, ubiquitinylation (UB), P2Y2,
intracellular CAp24, and GAPDH expressions. Data obtained from n = 3 independent experiments are presented as means ± SEM. Significance level is
**p% 0.01, unpaired t test.
(E–G) Tat-inducible b-Galactosidase reporter gene expressing HeLa CD4+CXCR4+ cells were depleted (E and F) or transfected (G) for NLRP3 for, respectively,
48 h (E and F) or 24 h (G), co-cultured with fusogenic HIV-1 envelope (Env) expressing HeLa cells (E–G), or infected with X4-tropic HIV-1NL4-3 (E–G) and evaluated
for HIV-1 Env-mediated fusion and for infection (E–G). Data obtained from n = 3 independent experiments are presented asmeans ± SEM. Significance levels are
***p% 0.001 and ****p% 0.0001, unpaired t test. See also Figures S5A, S5B, and S5C.
(H) Immunoprecipitations were performed in THP1 monocytes that were stimulated for 2 h with UTP and then infected with X4-tropic HIV-1NL4-3 for 6 h in the
presence of UTP. Representative western blots of two independent experiments are shown. See also Figures S5L and S5M.
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Figure 5. HIV-1 Viral Entry Is Controlled by E3 Ubiquitin Ligase CBL-Dependent Modulation of NLRP3 Expression
(A) NLRP3 and/or GFP-P2Y2 expressing cells were treated with 1 mM G5 or 10 mM MG132 and analyzed for NLRP3 and P2Y2 expressions.
(B) HEK293T cells expressing NLRP3 and GFP-P2Y2 were immunoprecipitated for NLRP3 and analyzed for ubiquitinylation (UB), SRC, NLRP3, and P2Y2 ex-
pressions.
(C) HEK293T cells expressing NLRP3, GFP-P2Y2, and/or SRC were analyzed for NLRP3, P2Y2, SRC, CBLY731*, and CBL expressions.
(D) NLRP3 and/or GFP-P2Y2 expressing cells were silenced for CBL and analyzed for NLRP3, P2Y2, and CBL expression. All protein expressions are performed
using western blot. Representative western blots of three independent experiments are shown in (A)–(D). Relative expression of NLRP3 data from n = 3 inde-
pendent experiments are presented as means ± SEM. Significance levels are *p% 0.05, **p% 0.01, ***p% 0.001, and ****p% 0.0001, unpaired t test.
(legend continued on next page)
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Despite the fact that P2Y2 protein levels increased, NLRP3 pro-
tein levels rapidly decreased after cell-free infection of MDMs
with R5-tropic HIV-1BaL (Figure 4A), THP1 monocytes (Figures
4B, S4A, S4B, and S4E–S4H) and CEM-SS T cells (Figures
S4C, S4D, and S4I–S4L) with X4-tropic HIV-1NL4-3 (Figures
4B, S4A, S4C, S4E, S4F, S4I, and S4J) or R5-tropic HIV-1AD8
(Figures S4B, S4D, S4G, S4H, S4K, and S4L), and PBLs with
X4-tropic HIV-1NDK (Figure 4C). However, NLRP3 mRNA ex-
pressions were not altered after infection of THP1 monocytes
(Figures S4M and S4N) and CEM-SS T cells (Figures S4O and
S4P) with X4-tropic HIV-1NL4-3 (Figures S4M and S4O) and
R5-tropic HIV-1AD8 (Figures S4N and S4P). The ubiquitin iso-
peptidase inhibitor G5 that was previously described as an
inducer of NLRP3 degradation (Py et al., 2013) decreased the
protein levels of NLRP3 (Figure 4D), thus suggesting that the
reduction of NLRP3 protein expression induced by HIV-1 infec-
tion must occur through post-transcriptional mechanisms. This
process is associated with the enhancement of P2Y2 expres-
sion and HIV-1 permissiveness of THP1 monocytes (as indi-
cated by the increased intracellular accumulation of HIV-1
capsid CAp24) (Figure 4D), in line with the hypothesis that
NLRP3 and P2Y2 control HIV-1 entry into target cells. Consis-
tently, we observed that the depletion or the overexpression
of NLRP3 (Figures S5A–S5C) enhanced or reduced, respec-
tively, HIV-1 Env-elicited fusion (Figures 4E–4G), the intracel-
lular accumulation of HIV-1 CAp24 capsid (Figures S5D–S5F),
and the susceptibility to HIV-1 infection (Figure 4E–4G), without
affecting the expression of the HIV-1 receptor CD4 and that of
its co-receptor CXCR4 (Figures S5G–S5I). Consistent with our
previous report (Se´ror et al., 2011), we confirmed that the
P2Y2 inhibitor AR-C118925XX (Figure S5J) and shRNA-medi-
ated P2Y2 depletion (Figure S5K) impaired the entry of
R5-tropic HIV-1AD8 into MDMs (Figure S5J) or of X4-tropic
HIV-1NL4-3 into THP1 monocytes (Figure S5K). This effect is
associated with the increased expression of NLRP3 in target
cells (Figure S5K). We also evaluated the impact of the
selective activation of P2Y2 by uridine triphosphate (UTP) in
THP1 cells infected with X4-tropic HIV-1NL4-3 for 6 h on the
NLRP3 and P2Y2 interaction and on the levels of NLRP3.
P2Y2 activation led to a significant enhancement of the
NLRP3-P2Y2 interaction associated with the degradation of
NLRP3 and an increase of HIV-1 entry into cells (Figures 4H,
S5L, and S5M). Altogether, these data indicate that the activa-
tion of P2Y2 occurring shortly after HIV-1 infection increases
the susceptibility of cells to viral entry by inducing NLRP3 pro-
tein degradation.
HIV-1 Envelope Overcomes NLRP3 Inhibition through
the Activation of the E3 Ubiquitin Ligase CBL
To define the molecular mechanisms accounting for the degra-
dation of NLRP3 during the early steps of infection, HEK293T
cells were transfected with full-length NLRP3, with GFP-tagged
full-length P2Y2, or with both constructs. Co-expression of GFP-
P2Y2 with NLRP3 reduced the expression of NLRP3 protein,
while co-expression of NLRP3 failed to reduce the expression
of GFP-P2Y2 (Figure 5A). The downregulation of NLRP3 by
P2Y2 was increased by the ubiquitin isopeptidase inhibitor G5
and fully blocked by the proteasome inhibitor MG132 (Figures
5A and S6A), thus demonstrating that upon P2Y2 activation,
NLRP3 is ubiquitinylated and degraded by the proteasome.
Considering that the ubiquitinylation and subsequent degrada-
tion of NLRP3 can be initiated by ubiquitin ligases such as E3
ubiquitin ligase CBL through its SRC kinase-dependent phos-
phorylation (on tyrosine 731, CBLY731*) (Kankkunen et al.,
2014; Py et al., 2013), we checked whether the kinase SRC
that was previously described as a downstream target of
P2Y2-dependent signaling pathway (Liu et al., 2004) may
interact with NLRP3 and control its degradation through the
activation of CBL. Indeed, the kinase SRC co-immunoprecipi-
tated with NLRP3 when NLRP3 was ubiquitinylated and
degraded (Figure 5B). Moreover, pharmacological inhibition of
SRC with PP1 or PP2 impaired the interaction between NLRP3
and P2Y2 (Figure S6B) and favored NLRP3 accumulation in
THP1 cells (Figure S6B). Moreover, in HEK293T cells, transfec-
tion of full-length SRC together with full-length NLRP3 and
GFP-tagged full-length P2Y2 led to an increased expression
and phosphorylation of CBL on tyrosine 731 (CBLY731*) as
well as to NLRP3 degradation (Figure 5C). Since the SRC kinase
is a candidate for proteasomal degradation through a CBL-
dependent process (Sandilands et al., 2012), we next investi-
gated the role of CBL in P2Y2-induced degradation of NLRP3.
Indeed, CBL depletion abolished the negative effect of GFP-
P2Y2 on the overall abundance of the NLRP3 protein (Figure 5D).
Altogether, these results suggest that P2Y2 controls NLRP3
(E–G) PHA/IL-2-stimulated human lymphocytes (E), MDMs (F), and THP1 cells (G) were infected, respectively, for 3, 3, or 6 hwith X4-tropic HIV-1NDK (E), R5-tropic
HIV-1BaL (F), or X4-tropic HIV-1NL4-3 (G) and analyzed by western blot for CBLY731* and CBL relative expressions. Representative western blots of three in-
dependent experiments are shown. Relative expressions data from n = 3 independent experiments are presented asmeans ± SEM. Significances are **p% 0.01,
***p% 0.001, and ****p% 0.0001, unpaired t test.
(H and I) Confocal microscopy image (H) of CBL and gp120 polarization during HIV-1-infected and uninfected lymphocyte interactions. Frequencies of CBL
polarization during HIV-1-infected and uninfected lymphocyte interactions are shown (I). Images are representative of three different donors. Data are presented
as means ± SEM, and significance is ****p% 0.0001 (n = 3 independent donors), unpaired t test.
(J) Intracellular CAp24 analyzed by western blot and its relative expression in control and CBL-depleted MDMs were infected for 6 h with HIV-1AD8. Repre-
sentative western blots of three independent experiments are shown. Relative expression data from three independent experiments are presented as means ±
SEM. Significance is ****p% 0.0001 (n = 3 independent donors), unpaired t test.
(K and L) Intracellular CAp24 analyzed by western blot of CBL-depleted CD4+CXCR4+ cells were infected with HIV-1NL4-3 (K) or HIV-1VSV-G (L) for 6 h. Repre-
sentative western blots of three independent experiments are shown. Relative expression from n = 3 independent experiments are presented as means ± SEM.
Significance is ****p% 0.0001, unpaired t test.
(M) Expressions of CBLY731*, CBL, P2Y2, and intracellular CAp24 analyzed by western blot in control and P2Y2-depleted THP1 macrophages infected for 6 h
with R5-tropic HIV-1AD8. Representative western blots of three independent experiments are shown. Relative expression of CBLY731* from n = 3 independent
experiments are presented as means ± SEM. Significance is ****p% 0.0001, unpaired t test.
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degradation through a pathway involving the CBL ubiquitin
ligase.
Next, we studied the role of the E3 ubiquitin ligase CBL during
the early steps of HIV-1 infection. We detected increased CBL
expression during cell-free infection of PBLs (Figure 5E),
MDMs (Figure 5F), and THP1 monocytes (Figure 5G). This pro-
cess was associated with the activating phosphorylation of
CBL on tyrosine 731 (CBLY731*) 3 h post-infection of macro-
phages with R5-tropic HIV-1BaL (Figure 5F). We also studied
the subcellular localization of CBL after co-culture of X4-tropic
HIV-1NDK-infected and uninfected PBLs. CBL polarized toward
the contact sites formed between HIV-1-infected and uninfected
cells (Figures 5H and 5I), where it colocalized with the HIV-1
glycoprotein gp120 (Figure 5H). Immunofluorescence micro-
scopy confirmed that the NLRP3/P2Y2 interaction occurs at
sites of viral entry during virological synapse formation between
HIV-1NDK-infected and uninfected lymphoblasts (Figures 1C–
1E), as well as upon cell-free infection of PBLs (Figures S1I
and S1J) or MDMs (Figures 1L and 1M). We finally determined
whether the E3 ubiquitin ligase CBL that is involved in the regu-
lation of NLRP3 expression (Figure 5D) and relocalizes to the
HIV-1-induced virological synapse (Figures 5H and 5I) might
control viral entry. MDMs (Figure 5J) or CD4+CXCR4+ HeLa cells
(Figure 5K) were depleted of CBL and infected for 6 h with
R5-HIV-1AD8 or X4-tropic HIV-1NL4-3, respectively. The depletion
of CBL inhibited HIV-1 entry into target cells (as indicated by
reduced intracellular HIV-1 CAp24 capsid; Figures 5J and 5K).
Moreover, CBL depletion failed to reduce cell permissiveness
to HIV-1VSV-G (Figure 5L), again suggesting that the E3 ubiquitin
ligase CBL controls P2Y2-dependent viral entry mediated by the
viral envelope. To demonstrate the functional link between
CBL function and P2Y2 activation during HIV-1 infection,
P2Y2-depleted THP1 macrophages and control cells were in-
fected with R5-tropic HIV-1AD8 for 6 h. P2Y2 depletion impaired
the activating phosphorylation of CBL on tyrosine 731
(CBLY731*) (Figure 5M). This effect was associated with
increased expression of NLRP3 and reduced entry of HIV-1
into target cells (Figure 5M). Altogether these results suggest
that the binding between HIV-1 Env and its host cell receptors
(CD4 and chemokine co-receptors) induces the recruitment of
the E3 ubiquitin ligase CBL to viral entry sites for modulating
the functional interaction between NLRP3 and P2Y2 interaction,
thus facilitating viral entry.
DISCUSSION
Deciphering the complex network of innate signaling pathways is
crucial for understanding the function of immune cells (such as
monocytes, macrophages, and dendritic cells) that might
constitute prime targets for prophylactic or therapeutic interven-
tion in various human pathologies (such as autoinflammatory,
autoimmune, infectious, and neoplastic diseases). Innate im-
mune signals reportedly play contrasting roles during the
acute and chronic phases of HIV-1 infection (Doitsh et al.,
2014). Recently, rapid inflammasome activation was reported
following SIV infection of Rhesus monkeys (Barouch et al.,
2016). During early SIV pathogenesis, NLRX1-mediated inhibi-
tion of inflammasome activation represses the transcription of
antiviral restriction factors (such as ISG5, MX2, APOBEC3,
and TRIM5) and facilitates early viral replication (Barouch et al.,
2016). Here, we report that the expression of NLRP3 proteins
is modulated through post-translational modifications during
the early steps of HIV-1 infection and controls target cell
susceptibility. We observed that following the binding of HIV-1
envelope to its host receptors (CD4, CXCR4, and/or CCR5),
the interaction between NLRP3 and P2Y2 rapidly increased
after HIV-1 infection, leading to the degradation of NLRP3 by
Figure 6. Model of HIV-1 Escape to NLRP3 Inhibition during the Early
Steps of Viral Entry
(A–C) NLRP3 interacts constitutively with P2Y2 and suppresses the phos-
phorylation of PYK2 (PYK2Y402*) and F-actin polymerization in host cells (A).
The binding of HIV-1 envelope to its receptor (CD4) and co-receptors (CXCR4
or CCR5) leads to rapid ATP release from host cells through pannexin-1 (PNX1)
and activates P2Y2. Once activated, P2Y2 enhances its interaction with
NLRP3 and activates and favors the recruitment of SRC andCBL toNLRP3 (B),
leading to NLRP3 ubiquitinylation and degradation. NLRP3 degradation leads
to PYK2 phosphorylation (PYK2Y402*) and subsequent F-actin polymeriza-
tion, which is required for the entry of HIV-1 into host cells (C).
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the E3 ubiquitin ligase CBL, thus favoring P2Y2-dependent viral
entry into target cells through PYK2-dependent F-actin
polymerization. Indeed, the interaction between HIV-1 Env and
its co-receptors enhances the interaction between NLRP3
and P2Y2 and subsequently induces the degradation of
NLRP3 by CBL, favoring the activation (phosphorylation)
of PYK2 (PYK2Y402*) and subsequent cytoskeletal rearrange-
ment (through F-actin polymerization) that facilitates HIV-1 early
membrane fusion with target cells (Jime´nez-Baranda et al.,
2007; Stolp and Fackler, 2011; Vorster et al., 2011) and hence
viral entry (Figure 6).
Our results are in agreement with published works supporting
the notion that polymorphisms affecting the NLRP3 gene could
influence the susceptibility to HIV-1 infection (Pontillo et al.,
2010, 2012) and coinfection with Mycobacterium tuberculosis
(Pontillo et al., 2013). Altogether, our results suggest that HIV-1
(through its envelope protein) hijacks the functional crosstalk
between NLRP3 and P2Y2 to optimize its viral life cycle.
The observation that the depletion of NLRP3 enhanced the
infectivity of host cells by HIV-1 suggests that NLRP3 proteins
function as intrinsic inhibitory factors for HIV-1 infection. In sharp
contrast to the vast majority of identified inhibitory factors that
Figure 7. NLRP3 Expression Is Increased in
Chronic HIV-1 and SIV Infection
(A–J) Quantification of NLRP3 and/or CD163 pos-
itive cells in lymph nodes (A, B, E, and F), brain
(C and D), colon (G and H), and ileum (I and J)
sections obtained from HIV-1-infected and unin-
fected patients (A–D) or from SIVmac251-infected
and uninfected Macaca fascicularis (E–J) are
shown. Images are representative of n = 6 HIV-1-
infected and n = 4 uninfected persons in (A), of
n = 3 HIV-1-infected and n = 3 uninfected persons
in (C), of n = 3 SIVmac251-infected and n = 3 un-
infected Macaca fascicularis in (G), and of n = 4
SIVmac251-infected and n = 3 uninfectedMacaca
fascicularis in (E) and (I). In (G), (H), (I), and (J), the
NLRP3 expression was analyzed in CD163 positive
macrophages. Data are presented in (B), (D), (F),
(H), and (J) as means ± SEM. Significance levels
are *p % 0.05, **p % 0.01, ***p % 0.001, and
****p% 0.0001, unpaired Mann-Whitney test.
impair viral infection at post-entry steps
(Harris et al., 2012), NLRP3 proteins limit
HIV-1 infection by interfering with viral
entry, suggesting that the NLRP3-P2Y2
interaction could be targeted for the pre-
vention and treatment of HIV-1 infection.
NLRP3 inflammasome activators (such
as LPS or MSU crystals) reduce the sus-
ceptibility of HIV-1 target cells through
the modulation of P2Y2-dependent
F-actin remodeling. Thus, strategies de-
signed to alter the functional interaction
between NLRP3 and P2Y2 could effec-
tively block HIV-1 infection. Nevertheless,
the identification of the inflammasome
inhibitor NLRX1 as transcriptional repressor of restriction factors
that impair viral replication (Barouch et al., 2016) underlines the
complexity of signaling pathways elicited by NLRP3 family
members during the early steps of HIV-1 infection. Further
molecular investigations are required to fully understand the
role of NLRP3 family members during these viral steps. Future
investigations must address the impact of the functional
NLRP3-P2Y2 interaction on cellular regulators that are known
to affect cortical F-actin rearrangement and to HIV-1 infection
such as LIM domain kinase 1 (Vorster et al., 2011), moesin (Bar-
rero-Villar et al., 2009), filamin-A (Jime´nez-Baranda et al., 2007),
and cofilin (Yoder et al., 2008).
There may be differences between the acute and the pro-
longed effects of HIV-1 on the aforementioned regulatory sys-
tem. Indeed, immunoreactive NLRP3 was detected at higher
levels in lymph nodes (Figures 7A and 7B) and in the frontal cor-
tex (Figures 7C and 7D) from untreated HIV-1 carriers, as
compared with uninfected specimens. Similar results were ob-
tained when comparing control tissues from the non-human
primate Macaca fascicularis with lymph nodes (Figures 7E and
7F) or intestinal tissues (colon in Figures 7G and 7H; ileum in
Figures 7I and 7J) from macaques infected with SIVmac251.
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NLRP3 expression was preferentially observed in CD163+
macrophages (Figures 7G, 7I, and 7J) that are known to express
P2Y2 (Elliott et al., 2009). After 21 days of infection of THP1
monocytes and CEM-SS T cells with X4- and R5-tropic viruses,
respectively, NLRP3 protein expression was increased (Figures
S7A–S7F, S7I, and S7J), although no modification of NLRP3
mRNA levels was detectable (Figures S7M–S7P). P2Y2 protein
expression did not change in CEM-SS T cells but increased
after 21 days of infection of THP1 monocytes (Figures S7G,
S7H, S7K, and S7L). Altogether, these results suggest that
the molecular mechanisms involved in the enhanced interaction
between NLRP3 and P2Y2 that is detected during chronic
infection with HIV-1 may be distinct from those detected in the
early steps of HIV-1 infection. The increased NLRP3 expression
during chronic HIV-1 infection is consistent with recent findings
showing that HIV-1 activates NLRP3 inflammasome through
Tat and Vpr proteins in lymphocytes, microglial cells, and mac-
rophages (Bandera et al., 2018; Chivero et al., 2017; Haque
et al., 2016; Mamik et al., 2017). Thus, NLRP3 may play a dual
opposite role during early steps of infection by inhibiting viral
entry and at the later post-entry steps by contributing to neuro-
inflammation and immune activation associated with HIV-1
infection.
The blockade of immune checkpoints in lymphocytes has
recently emerged as a new and promising approach for
treating both chronic viral infection and cancer. Here, we identi-
fied a functional interaction that acts on myeloid cells and that
could be exploited for the development of HIV vaccines or
therapeutic combinations to cure HIV infection (Barouch et al.,
2016) and potentially other viral infections (such as hepatitis B
and C). In addition, it appears likely that the NLRP3-P2Y2
interaction could be manipulated for the treatment of HIV-1-
associated brain disease, which is also associated with strong
activation of the NLRP3 inflammasome (Walsh et al., 2014).
Future studies should explore the possibility of modulating the
NLRP3-P2Y2 functional interaction with the aim of treating hu-
man diseases that are triggered by excessive activation of the
NLRP3 inflammasome, such as cryopyrin-associated periodic
syndromes (Agostini et al., 2004), rheumatoid arthritis (Vande
Walle et al., 2014), obesity (Vandanmagsar et al., 2011), or
Alzheimer’s disease (Halle et al., 2008).
Thus, our data demonstrate a constitutive interaction
between NLRP3 and P2Y2 that could be targeted to reduce
viral propagation and improve the immune response against
HIV infection.
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LEAD CONTACT AND MATERIALS AVAILABILITY
Further information for resources and reagents should be directed to and will be provided by the Lead Contact, Jean-Luc Perfettini
(perfettini@orange.fr).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell lines
The monocyte THP1 cells and CEM-SS T cells were maintained in RMPI-1640-Glutamax medium supplemented with 10% heat
inactivated fetal bovine serum (FBS) and 100 UI/mL penicillin-streptomycin (Life technology). THP1 cells were obtained from
ATCC. THP1 macrophages were obtained by treatment for 3 hours with 100 nM phorbol-12-myristate-13-acetate (PMA, Invivogen)
of THP1 monocytes and after extensive washings were let to differentiate for 72 hours before experimentation. HeLa cells stably
transfected with the Env gene of HIV-1LAI/IIIB (HeLa Env
+), HeLa cells transfected with CD4 (HeLa CD4+CXCR4+), HeLa TZM-bl
and HEK293T cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM)-Glutamax supplemented with 10% FBS and
100 UI/ml penicillin-streptomycin, in the absence or presence of the indicated concentrations of inhibitors. All cell lines used were
mycoplasma-free.
Primary Cells
To generate Monocytes Derived Macrophages (MDMs) for HIV-1 infections with HIV-1BaL, CD14
+ monocytes were isolated from pe-
ripheral blood mononuclear cells (PBMCs) by positive selection using anti-CD14 beads (Miltenyi Biotec). Buffy coats from healthy
Continued
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Oligonucleotides
NLRP3 Taqman predesigned probe ThermoFisher scientific 4331182 (Hs00918082_m1)
GAPDH TaqMan predesigned probe ThermoFisher scientific 4331182 (Hs02758991_g1)
siRNA control for siNLRP3 1 and 2 This paper (Table S1) N/A
siNLRP3 1 and 2 siRNAs This paper (Table S1) N/A
siGenome Non Targeting SMART siRNA
Pool for SMART pool siRNA
Dharmacon (Table S1) D-001206-13-20
siGENOME SMART pool human CBL siRNA Dharmacon (Table S1) M-003003-02-0005
Early Reverse transcripts primers and probes G. Pancino (Table S1) (David et al., 2006)
PLKO.1- shRNAs This paper (Table S1) N/A
Recombinant DNA
pUNO-NLRP3 InvivoGen puno1-hnalp3
pFlag-Luciferase A. Allouch (Allouch et al., 2011)
33Flag-pcDNA3 G. Nunez (He et al., 2014)
33Flag-pcDNA3 NLRP3 G. Nunez (He et al., 2014)
pEFGP-N1-P2Y2 L. Erb (Seye et al., 2004)
pGFP-Vpr G. Pancino NA
pHIV-1NL4-3 J.-L. Perfettini (Se´ror et al., 2011)
pHIV-1NL4-3DENV J.-L. Perfettini (Se´ror et al., 2011)
pHIV-1AD8 NIH AIDS Reagent program (Se´ror et al., 2011)
pMDG-VSV-G J.-L. Perfettini (Se´ror et al., 2011)
pCMV GAG-POL-HIV M. Caillet (Caillet et al., 2011)
Software and Algorithms
Image J https://imagej.nih.gov/ij/ N/A
Icy http://icy.bioimageanalysis.org/download N/A
GraphPad Prism version 6.0 https://www.graphpad.com/ N/A
Other
AB human serum Male HIV tested Biowest S4190-100
Hoechst 33342 Invitrogen H3570
Protein G Sepharose 4 Fast Flow GE healthcare 17-0618-01
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donors were obtained from the French blood bank (Etablissement Franc¸ais du Sang (EFS)). In accordance with French law, written
informed consent to use the cells for clinical research was obtained from each donor. Purified monocytes were incubated in RMPI-
1640-Glutamaxmedium supplemented with 100 UI/ml penicillin-streptomycin and with 10%FBS in the presence of 10 ng/ml recom-
binant human (rh) M-CSF (PeproTech). After 6 days of culture, adherent cells corresponding to the macrophages enriched fraction
were harvested, washed and used for HIV-1BaL infection experiments. Formacrophage silencing and infectionswith HIV-1AD8,mono-
cytes were separated from PBMCs by adherence to the plastic, detached and cultured for 6 days in hydrophobic Teflon dishes
(Lumox Duthsher) in macrophage medium (RPMI 1640 supplemented with 200 mM L-glutamine, 100 U of penicillin, 100 mg strepto-
mycin, 10mMHEPES, 10mMsodiumpyruvate, 50 mM b-mercaptoethanol, 1%minimum essential medium vitamins, 1%non-essen-
tial amino acids (Life technology)) supplemented with 15% of heat inactivated human serum AB (Life technology or Biowest). For
experiments, MDMs were harvested and resuspended in macrophage medium containing 10% of FBS. MDMs obtained with this
method are 91 to 96% CD14+, they express: the differentiation markers (CD11b and CD71) and the M2 macrophage polarization
markers (CD163 and CD206) (Allouch et al., 2013).
T cells were prepared from themonocyte depleted cell fraction of PBMCs. Peripheral blood lymphocytes (PBLs) were activated for
48 hours in freshmedium supplementedwith 2.5 mg/ml PHA (Sigma-Aldrich) and 1 mg/ml rhIL-2 (PeproTech). PBLswere thenwashed
and cultured in growth medium containing 1 mg/mL rhIL-2 for 24 hours before HIV-1 infections.
Non-Human primates
Adult cynomolgus macaques (Macaca fascicularis) (four males and three females) were imported from Mauritius and housed in the
facilities of the ‘‘Commissariat a` l’Energie Atomique et aux Energies Alternatives’’ (CEA, Fontenay-aux-Roses, France). The protocols
employed were approved by the ethical committee of the CEA ‘‘Comite´ d’Ethique en Experimentation Animale’’ registered in the
French Research Ministry under number 44. Samples from lymph nodes, ileum and colon tissues were obtained from Macaca fas-
cicularis that have been infected at the age of 5 years old by intrarectal inoculation with a single dose of 50 50% animal infectious
doses (AID50) of SIVmac251. Tissues were collected during animal necropsy (for SIVmac251-infected animals, on days 701 to 738 after
SIV infection) after sedation of the animals (ketamine chlorhydrate 10 mg/kg) followed by euthanasia (injection of sodium pentobar-
bital 180 mg/kg). Non-human primates (NHP, which includes M. fascicularis) were used at the CEA in accordance with French
national regulation and under national veterinary inspectors (CEA Permit Number A 92-032-02). The CEA is in compliance with
Standards for Human Care and Use of Laboratory of the Office for Laboratory Animal Welfare (OLAW, USA) under OLAW Assurance
number #A5826-01. The use of NHP at CEA is also in accordance with recommendation of the European Directive (2010/63, recom-
mendation N9). Animals were housed in adjoining individual cages allowing social interactions, under controlled conditions of
humidity, temperature and light (12-hour light/12-hour dark cycles). Water was available ad libitum. Animals were monitored and
fed 1-2 times daily with commercial monkey chow and fruits by trained personnel. Macaques were provided with environmental
enrichment including toys, novel foodstuffs and music under the supervision of the CEA Animal Welfare Body. The animals were
used under the supervision of the veterinarians in charge of the animal facility. Experimental procedures were conducted after animal
sedation with ketamine chlorydrate (Rhone-Merieux, Lyon, France, 10 mg/kg) as previously described (Dioszeghy et al., 2006).
Human autopsies
Human autopsies from axillary lymph nodes and frontal cortex were obtained in accordance with the Italian and EU legislations, after
approval by the Institutional Review Board of the Lazzaro Spallanzani National Institute for Infectious Disease (Ethics Committee
approval number 40/2006). Axillary lymph nodes and post-mortem frontal cortex sections were obtained from healthy (6 and 5,
respectively) and HIV-1- infected individuals (6 and 11, respectively) (all men, mean age 36 years, the median values of HIV-1 viral
load was 4.5 ± 0.6 log10 cp/ml and < 500 CD4 T cells/ml). Frontal cortex sections were obtained from patients with HIV-1-associated
dementia.
METHODS DETAILS
Plasmids and transfections
NLRP3 coding sequence in the pUNO vector was purchased from Invivogen. The Flag-tagged NLRP3 full-length coding sequence
was inserted in the 3xFlag-pcDNA3 and are a kind of gift from Gabriel Nunez (He et al., 2014). The sequence coding for P2Y2 (in the
pEFGP-N1 vector) is gift from Laura Erb (Seye et al., 2004). Transient transfections of HeLa CD4+CXCR4+ cells (2.4x105) or HEK293T
(3x105) cells withmammalian expression vectors (1-5 mg) were performed using Fugene transfection reagent (Promega), following the
manufacturer’s instructions. Western blot, immunoprecipitation analyses and experiences of HIV-1 infection or cell fusion were per-
formed 24 hours after transfection. The transfection of pHIV-1AD8 and pHIV-1NL4-3 in HEK293T were performed 48 hours after trans-
fection of pFlag-Luciferase or p3xFlag-NLRP3.
siRNA- and shRNA-mediated knockdowns
For HeLa CD4+CXCR4+ knockdown the small interfering RNAs (siRNAs) used against NLRP3 were purchased from Sigma and had
the following sequences: NLRP3, siRNA-1, 50-GGAUCAAACUACUCUGUGA-30; siRNA-2, 50-UGCAAGAUCUCUCAGCAAA-30 and
the corresponding control siRNA, 50-UUCAAUAAAUUCUUGAGGU-30. The siRNAs against CBL used for primary MDMs and
e4 Cell Reports 28, 3381–3394.e1–e7, September 24, 2019
HEK293T cells are siGenome (Dharmacon) smart pool selected composed of a pool of four siRNAs having the following sequences
for CBL (siRNA1, 50-GGAGACACAUUUCGGAUUA-30; siRNA2, 50-GAUCUGACCUGCAAUGAUU-30; siRNA3, 50-GACAAUCCCUCA
CAAUAAA-30; siRNA4, 50-CCAGAAAGCUUUGGUCAUU-30). The siRNAs used as control with siGenome smart pool are a pool of four
on target plus non-targeting siRNAs (Dharmacon). siRNAs transfection of HeLa CD4+CXCR4+ or HEK293T cells were performed with
20 nM siRNA using Oligofectamine (Invitrogen) according to the manufacturer’s instructions. Western blot analyses and experiences
of HIV-1 infections or cell fusions were performed 48 hours after siRNA transfection. For siRNA transfection of MDMs, the protocol
was previously described (Allouch et al., 2013): MDMs were seeded (0.5x106 MDMs/0.5 ml/ well of 12-well plate in macrophages
medium + 10% FBS) and let to be attached at 37C for 2 hours prior siRNAs transfection. The siRNAs transfections were performed
with the INTERFERin (Polyplus Transfection). Different amounts of siRNAs were pre-diluted in 1 mL of Opti-MEM in which 20 mL of
INTERFERin were added and the transfection mix was let to incubate at room temperature for 10 minutes. The transfection
mix (250 ml) was added to 0.5x106 MDMs at the final concentrations of 50 nM of siRNAs against CBL. Equal amounts of the on target
plus non-targeting siRNAs were added to the control MDMs. TheMDMswere then incubated at 37C for overnight. Themediumwas
replaced with fresh macrophage medium supplemented with 10% FBS prior to the infections. At 72 hours post-CBL siRNA trans-
fection MDMs were infected with HIV-1AD8 (MOI of 1) for 6 hours, cell lysates were assayed for protein expression by western blot.
For short hairpin RNA (shRNA) lentiviral particles transduction, the pLKO.1 shRNA expression lentiviral vector coding for each
targeted gene was purchased from Thermo Scientific. The shRNAs used in knockdown experiments had the following sequences
for P2Y2 (shRNA1, 50-ATGTTCCACCTGGCTGTGTCTGATGCACT-30), for NLRP3 (shRNA1, 50-TTCTTGAAGTGTTTCTAACGC-30,
shRNA2, 50-AAACAGTAGAACAATTCCAGC-30) and pLKO.1 empty vector control. Lentiviral vector particles were generated by
cotransfection of three plasmids coding for the gag-pol HIV-1 genes (pCMV- HIV-1-GAG-POL), for the vector genome carrying
shRNA of interest (pLKO.1 shRNA) and for the plasmid coding for an envelope of VSVG (pMDG-VSV-G). Co-transfection was per-
formed in HEK293T cells using Fugene transfection reagent (Promega) according to the manufacturer’s protocol. Two days after
transfection, supernatants were filtered using 0.45-mm cellulose acetate filters (Sartorius stedim), aliquoted and frozen at 80C.
For transduction, lentivirus productions were added to the monocytic THP1 cell line (4x106) or into CD4+CXR4+ HeLa cells (106)
and 24 hours after transduction the medium was replaced with fresh growth medium containing 1 mg/mL puromycin (Invivogen).
MDMs, CEM-SS T Cells or THP1 cells (1x106) were transduced with 2 mg CAp24 of a pool of LKO.1 shNLRP3 (shRNA1 and shRNA2)
for 48 hours before infections with HIV-1NL4-3 or HIV-1AD8 (MOI of 1).
Virus productions
To produce stocks of wild-type HIV-1NL4-3 or HIV-1AD8, HEK293T cells (2x10
6) were transfected with 20 mg of the corresponding
proviral DNA (pHIV-1NL4-3 or pHIV-1AD8) and for Env-deleted VSV-G pseudotyped NL4-3 viruses (pHIV-1NL4-3DEnv), HEK293T cells
(2x106) cells were transfected with 4 mg of VSV-G expression vector (pVSV-G) and 16 mg of HIV-1 proviral DNA (pHIV-1NL4-3DEnv)
by the calcium phosphate method. After 12 hours, the transfection mixture was replaced with 8 mL of fresh growth medium.
Then, 24 hours later, the media containing the first batch of virus was harvested and 8 mL of fresh growth medium was added to
the cells for additional 24 hours. HIV-1NDK and HIV-1BaL were obtained after infection of activated PBLs and MDM with HIV-1NDK
and HIV-1BaL viral stocks, respectively and harvesting the corresponding supernatants at three and six days after infections (Saı¨di
et al., 2008). HIV-1AD8-Vpr-GFP was obtained through the transfection of 3x10
6 HEK293T cells with 10 mg pHIV-1AD8 (NIH AIDS research
reagents), 2.5 mg pGFP-Vpr expression vectors using Fugene (Promega) following manufacturer’s instructions.
Upon collection, all virus-containingmedia was low-speed centrifuged, filtered through a 0.45 mmpore size filter (Sartorius stedim),
to remove cell debris, treated with Benzonase (Novagen) and stored in 1 mL aliquots at 80C (Delelis et al., 2009; Perfettini et al.,
2004, 2005). Viral stocks were standardized by quantification of CAp24 antigen in cell culture supernatants with an enzyme-linked
immunoabsorbent assay (Perkin Elmer) and infection of TZM-bl cells (bearing the b-galactosidase gene under the control of HIV-1
LTR) with serial dilutions of the viral stocks followed by cell fixation and X-Gal staining. The multiplicity of infection (MOI) was deter-
mined at 48 hours of infection of TZM-bl based on the number of the positive X-Gal cells.
Viral infections
After 3 days of infection with HIV-1NDK (MOI of 1), PHA/IL-2–stimulated peripheral blood lymphocytes were cocultured with unin-
fected lymphoblasts or alone for 48 hours and analyzed by immunofluorescence for synapse formation. MDMs were infected with
HIV-1BaL (with a MOI of 2) during 3 days for the analysis by Proximity Ligation Assay (PLA) (following manufacturer’s instructions)
and the intracellular CAp24 by FACS, as previously described (Se´ror et al., 2011), for MSU (100 mM) and LPS (10 ng/ml) treated cells.
MDMs or PMA-THP1 macrophages infected with HIV-1AD8 were pre-treated 18 hours with MSU (100 mM) and AR-C118925XX
(100 mM) and infected during six hours with HIV-1AD8 (MOI of 1) in the presence of the indicated drugs. The quantification of the
LDH release in the cell supernatants of MSU-treated MDM was performed using the commercially available ELISA kits for LDH
(Roche) according to the manufacturers’ instructions at 24 hours after infection.
THP1 cells were also infected with HIV-1NL4-3 (MOI of 1) or HIV-1NL4-3DEnv (MOI of 1) during 6 hours and analyzed for
related signaling pathways by western blot. THP1 monocytes or CEM-SS T cells were infected or not for 3 hours with X4-tropic
HIV-1NL4-3 or R5-tropic HIV-1AD8 (MOI of 1) and then were either harvest for western blot and mRNA analysis or kept for 21 days
by passing cells every 3 days for the same analysis.
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For THP1monocytes or CEM-SS T cells silenced for NLRP3, through the transduction of lentiviral vectors expressing shRNA1 and
shRNA2 against NLRP3 gene, and control cells were infected with HIV-1NL4-3 or HIV-1AD8 (MOI of 1) at 48 hours after shRNA trans-
duction for 6 hours and after washings were suspended in equal medium volumes. Cell supernatants were then harvested at 6 and
12 days after infection for quantification of HIV-1 CAp24 contents. For immunoprecipitation assays, THP1 cells were treated 8 hours
with PP1 (20 mM), PP2 (20 mM) or 2 hours of pretreatment with UTP (100 mM) before infection. Then, THP1 cells were infected during
6 hours with HIV-1NL4-3 (MOI of 1) in the presence of the indicated drugs. To remove the membrane bound non-internalized HIV-1
particles before analysis of intracellular CAp24 by western blot, cells were treated with trypsin at 37C for 20 minutes followed by
two extensive washings. Target cell infectivity was evaluated using the enhanced b-galactosidase assay kit (Roche). PMA-THP1
macrophages were infected with HIV-1AD8-Vpr-GFP (MOI of 1) in the presence of latrunculin B (10 mM) during 6 hours and the control
cells were treated with ethanol and then were fixed with 2% PFA for immunofluorescence analysis.
Immunofluorescence
Cells were fixed in 2% paraformaldehyde-PBS for 5 minutes, permeabilized in 0.3% Triton (Sigma) in PBS or 0.1% Triton for MDMs
and PBLs, and incubated with PBS-FBS 20% for 1 hour. Tissue 4-mm sections (lymph nodes, ileum and colon tissues) were cut from
the paraffin blocks of the paraformaldehyde fixed tissues from Macaca fascicularis or humans. After paraffin removal, slides were
subjected to antigen retrieval by microwave boiling in 1 mmol/l EDTA pH 9.0. Cell slides were then incubated during overnight for
immunofluorescence with anti-P2Y2 (Alomone), anti-NLRP3 (Adipogen), anti-CD163 (BD laboratories) or anti-gp120 (2G12) (AIDS
Research and Reference Reagent Program, Division of AIDS, NIAID) or for immunochemistry with anti-NLRP3 (Sigma) after perme-
abilization in 0.3% Triton for 5 minutes and saturation in PBS-FBS 20% for 1 hour. Then, cells were incubated with appropriate sec-
ondary antibodies conjugated to Alexa Fluor 488, 546 or 647 fluorochromes (Life technologies) at room temperature during 1 hour
and 30minutes. Actin was stainedwith Alexa Fluor 594 Phalloidin for 30minutes at room temperature. DNAwas stainedwith Hoechst
33342, Trihydrochloride, Trihydrate (Life technologies) and then cells were mounted with Flouromount Gmedium (Southern biotech).
Proximity Ligation Assay (DUOLINK, Sigma) was performed according to the manufacturer’s instructions using anti-NLRP3 (Adip-
ogen) and anti P2Y2 (Alomone) as primary antibodies. Images of cells were acquired by laser-scanning fluorescent confocal micro-
scopy Leica SPE with LAS-X software (Leica) with 8 bits configuration and using a 63X oil objective (1.4 numerical aperture). Leica
Microsystem immersion oil (11513859) was used and imaging was performed at room temperature. Confocal images were analyzed
with ImageJ and exported as TIFs for figures illustration. For 3D immunofluorescence intensity image construction, images were
analyzed by Icy software (in Figure 1G).
Western blots and immunoprecipitations
Cells werewashed twicewith PBS and lysed in appropriated buffer (250mMNaCl, 0.1%NP-40, 5mMEDTA, 10mMNa3VO4, 10mM
NaF, 5 mM DTT, 3 mM Na4P2O7, 1 mM EGTA, 10 mM Glycerol phosphate, 10 mM Tris-Hcl (pH = 7.5) and the protease and phos-
phatase inhibitors (Roche)). 10-40 mg of protein extracts were run on 4%–12% or 10% SDS-PAGE and transferred at 4C onto a
nitrocellulose membrane (0.2 Micron). After incubation for 2 hours at room temperature with 5% nonfat milk or BSA (Bovine Serum
Albumin) in Tris-buffered saline and 0.1% Tween 20 (TBS-Tween), membranes were incubated with primary antibody at 4C over-
night. Horseradish peroxidase–conjugated goat anti–mouse or anti–rabbit (SouthernBiotech) antibodies were then incubated for
1 hour 30 minutes and revealed with the enhanced ECL detection system (GE Healthcare) in the linear range. The primary antibodies
for western blot against CBL (D4E10), GFP (D5.1), PYK2 (5E2), PYK2Y402*, SRC (36D10) and SRCY416* were obtained from Cell
Signaling. Primary antibodies against ACTIN and GAPDH were purchased from Abcam and Millipore, respectively. The primary an-
tibodies anti-CAp24 (42-50) and anti-gp120 (2G12) were from NIH (AIDS Research and Reference Reagent Program, Division of
AIDS, NIAID). Antibody anti-NLRP3 was from Adipogen (Cryo-2), anti-P2Y2 was from Alomone, anti-ubiquitin (UB) (P4D1) was
from Santa-Cruz, and anti-Flag was from Sigma. For immunoprecipitations, cell pellets were lysed at indicated times after infection
or 24 hours after transfection in CHAPS buffer (50 mM Tris- HCl (pH = 7.5), 0.50 M NaCl and 0.1% CHAPS) containing protease and
phosphatase inhibitors. Anti-P2Y2 (Alomone) antibodies were incubated overnight at 4C with 500 mg cell lysates. The complexes
were precipitated by incubation with Protein G Sepharose 4 Fast Flow (GE Healthcare) for 4 hours. For relative expression quantifi-
cation analyzed protein bands were quantified by ImageJ software and normalized on the corresponding endogenous expression of
GAPDH or ACTIN proteins. To determine the relative NLRP3 interacting with P2Y2, NLRP3 protein bands were normalized on the
corresponding immunoprecipitated P2Y2.
Flow cytometry
For flow cytometry, THP1 cells and MDMs (106 cells/ml) were harvested in RPMI complete medium, washed twice with PBS, satu-
rated at 4C for 20 min with PBS-FBS 10% and incubated with anti-CD4 (FITC) and anti-CD184 (CXCR4) (PE-Cy5) antibodies. The
indicated antibodies and isotype-matched antibodies used were obtained from BD PharMingen. Phenotypic analyses on primary
human MDMs infected by HIV-1BaL were realized by flow cytometry using mAb anti-CD163 (FITC) (BioLegend), anti-CD206 (Alexa
Fluor647 (AbD Serotec) and anti-p24 (PE) (Beckman Coulter).
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Quantitative PCR (qPCR)
The quantification of the HIV-1 early reverse transcripts (ERT) was based on the quantification of HIV-1 R-U5 DNA and performed as
previously described (David et al., 2006). DNA was extracted with the DNeasy Tissue Kit (QIAGEN) at 24 h.p.i for ERT detection in
MDMs. The quantitative PCR analysis was carried on an ABI prism 7000 Sequence Detection System. The amounts of HIV-1
cDNA copies were normalized to the endogenous reference gene albumin. Standard curve were generated by serial dilutions of a
commercial human genomic DNA (Roche).
For the detection of NLRP3 mRNA, total RNA from 0.25x206 THP1 monocytes or CEM-SS T cells were extracted using RNeasy kit
(QIAGEN). RNA was transcribed using SuperScript II RT (Invitrogen). The predesigned Applied Biosystems probes for NLRP3 gene
(Hs00918082 m1) and GAPDH (Hs02758991 g1) (for normalization) were used. These probes were included in the premade TaqMan
Gene expression mixes obtained from thermofisher scientific. The results were analyzed with the cycle threshold method (CT) and
each sample was normalized to the quantity of endogenous GAPDH mRNA.
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical parameters including exact values of n, precisions measures (mean ± SEM), statistical significances and the tests used for
each analysis are reported in the Figures and Figures legends. All values were expressed as the mean ± SEM of cell individual sam-
ples. Samples values were analyzed using two-tailed unpaired Student’s t test for two groups, ANOVA for multiple comparisons
groups, Mann-Whitney test for humanMDMs and PBLs donors not normalized data andWilcoxon signed rank test for MDMs donors
analyzed for early reverse transcripts. Significance levels are * p% 0.05, ** p% 0.01, *** p% 0.001 and **** p% 0.0001. Statistical
analysis was performed in GraphPad Prism version 6.0b (GraphPad Software). No statistical test was used to determine sample size.
No samples were excluded for analysis. The experiments were not randomized. Investigators were not blinded to allocation during
experiments and outcome assessments.
DATA AND CODE AVAILABILITY
The western blot data reported in this paper have been deposited on Mendeley Data (Mendeley data https://doi.org/10.17632/
6bxgc4h4m2.1) and are accessible to readers upon request.
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